Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2012
12/12/2012CN101575278B Method for preparing high purity dihydroirisquinone, pallason B
12/12/2012CN101575277B Method for preparing high purity irisquinone, pallason A
12/12/2012CN101560243B Method for separating and purifying abrin and product thereof
12/12/2012CN101525364B Crystal form of fulvestrant and preparation method thereof
12/12/2012CN101511813B Heterocyclic FXR binding compounds
12/12/2012CN101370803B Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
12/12/2012CN101340910B Treatment of drug-resistant tumors
12/12/2012CN101319247B IL-2 selective agonists and antagonists
12/12/2012CN101253168B Substituted benzimidazoles as kinase inhibitors
12/12/2012CN101223150B Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
12/11/2012US8330026 Derivatives of the NF-κB inducing enzyme, their preparation and use
12/11/2012US8329928 Compounds, compositions and methods
12/11/2012US8329900 Immunosuppressants; autoimmune disease; antiinflammatory agents; multiple sclerosis; rheumatic diseases; antiarthritic agents; aids; preparing, for example, 2-{6-[3-Amino-piperidin-1-yl]-3-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile
12/11/2012US8329862 Cell-killing peptide derived from the C-terminus of NOXA protein
12/11/2012US8329861 Protein KTPAF50
12/11/2012US8329859 Peptides that home to tumor lymphatic vasculature and methods of using same
12/11/2012US8329742 Macrocyclic compounds useful as pharmaceuticals
12/11/2012US8329714 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
12/11/2012US8329701 Dihydrofuro pyrimidines as AKT protein kinase inhibitors
12/11/2012US8329690 Cyclothiocarbamate derivatives as progesterone receptor modulators
12/11/2012US8329682 Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
12/11/2012US8329680 Formulation
12/11/2012US8329666 Compositions and methods for treating cancer
12/11/2012US8329665 Compositions and methods for treating cancer
12/11/2012US8329662 Prodrug of an ICE inhibitor
12/11/2012US8329463 RNA interference mediating small RNA molecules
12/11/2012US8329180 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
12/11/2012US8329172 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
12/11/2012US8329164 Methods and compositions concerning poxviruses and cancer
12/11/2012CA2652048C Method and compositions for treating hematological malignancies
12/11/2012CA2650202C Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
12/11/2012CA2576144C Sigma receptor inhibitors
12/11/2012CA2565237C Quinoxaline inhibitors of hedgehog signalling
12/11/2012CA2549628C Fused pyrrolocarbazoles and methods for the preparation thereof
12/11/2012CA2549627C Novel fused pyrrolocarbazoles
12/11/2012CA2513104C Survivin-derived peptides and use thereof
12/11/2012CA2483890C Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
12/11/2012CA2451980C 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune disorders
12/06/2012WO2012167230A1 In situ antigen-generating cancer vaccine
12/06/2012WO2012167101A1 Ovarian cancer stem cells and methods of isolation and uses thereof
12/06/2012WO2012167099A1 Biomarkers and therapy for cancer
12/06/2012WO2012167081A1 Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
12/06/2012WO2012166987A2 Liphagal enantiomers and their derivatives and precursors, and enantioselective methods of making the same
12/06/2012WO2012166983A1 Tricyclic inhibitors of poly(adp-ribose)polymerase
12/06/2012WO2012166903A1 Methods and uses for ex vivo tissue culture systems
12/06/2012WO2012166778A2 Conjugates of nitroimidazoles and their use as chemotherapeutic agents
12/06/2012WO2012166722A1 Treating colorectal, pancreatic, and lung cancer
12/06/2012WO2012166712A1 Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
12/06/2012WO2012166705A2 Supramolecular nanofibers and hydrogels based on amino acid-nucleobase-glycoside conjugates
12/06/2012WO2012166588A2 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
12/06/2012WO2012166560A1 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
12/06/2012WO2012166559A1 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
12/06/2012WO2012166555A1 Water - soluble polymer - linked binding moiety and drug compounds
12/06/2012WO2012166415A1 Heterocyclic autotaxin inhibitors and uses thereof
12/06/2012WO2012166151A1 Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
12/06/2012WO2012165995A1 Photodynamic treatment method for malignant tumors
12/06/2012WO2012165854A2 Long interfering dsrna simultaneously inducing an immune reaction and the inhibition of the expression of target genes
12/06/2012WO2012165815A2 Nano-vehicle derived from tumor tissue, and cancer vaccine using same
12/06/2012WO2012165653A1 Improved oligonucleotide and pharmaceutical composition containing said oligonucleotide
12/06/2012WO2012165394A1 Anti-tumor agent
12/06/2012WO2012165262A1 Benzylamine derivative
12/06/2012WO2012164969A1 Pharmaceutical composition for preventing and/or treating cancer, containing substituted phenanthrene compound as active ingredient
12/06/2012WO2012164936A1 Suv39h2 as a target gene for cancer therapy and diagnosis
12/06/2012WO2012164578A1 Compositions and methods for preparing immediate release formulations of nilotinib
12/06/2012WO2012164497A1 A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck
12/06/2012WO2012164326A1 Combined pharmaceutical compositions for the treatment of tumours
12/06/2012WO2012164118A1 Bioactive polyphenolic compounds containing sulphur or selenium and uses thereof
12/06/2012WO2012164060A1 Methods of treating mesothelioma with a pi3k inhibitor compound
12/06/2012WO2012164004A1 Novel antigen peptide and uses thereof
12/06/2012WO2012163942A1 Substituted aminoimidazopyridazines
12/06/2012WO2012163934A1 Amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives as new potent kinase inhibitors
12/06/2012WO2012163933A1 Amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives as new potent kinase inhibitors
12/06/2012WO2012163814A1 Cancer treatment by combining dna molecules mimicking double strand breaks with hyperthermia
12/06/2012WO2012163544A1 Removal of soluble tumor necrosis factor receptor 2 (stnfr2)
12/06/2012WO2012163291A1 Phenylpiperazine derivative for inhibiting tumor metastasis and tumor angiogenesis
12/06/2012WO2012163264A1 Saucernetin structurally simplified substance and preparation method therefor and pharmaceutical composition and use thereof
12/06/2012WO2012163236A1 Pyridothiazepine derivative, preparation method and uses therefor
12/06/2012WO2012163174A1 Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof
12/06/2012WO2012163119A1 Construction and application of mutant type b human adenovirus ad11 having enhanced oncolytic power
12/06/2012WO2012162828A1 Matriptase inhibitors and uses thereof against orthomyxoviridae infections
12/06/2012WO2012162812A1 Polymorphism panels predictive of anthracycline-induced cardiotoxicity (act)
12/06/2012WO2012162807A1 Brain tumor targeting peptides and methods
12/06/2012WO2012135856A3 Very low dose vinorelbine for treatment of cancer
12/06/2012WO2012135397A3 Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
12/06/2012WO2012127506A4 Substituted fused tricyclic compounds, compositions and medicinal applications thereof
12/06/2012WO2012125447A3 Piperazinedione compounds
12/06/2012WO2012099424A3 Composition and functional health food comprising fenugreek extracts for treating brain cancer
12/06/2012WO2012099422A3 Composition and functional health food comprising lysimachiae foenum-graeci herba extracts for treating brain cancer
12/06/2012WO2012099420A3 Composition and functional health food comprising elecampane extracts for treating brain cancer
12/06/2012WO2012099419A3 Composition and functional health food comprising cirsium japonicum extracts for treating brain cancer
12/06/2012WO2012093919A3 Composition for treating leukemia and method for preparing myrrh extract
12/06/2012WO2012093918A3 Composition including thistle root extract and functional health food
12/06/2012WO2012093917A3 Composition including tussalingo farafara l. extract and functional health food
12/06/2012WO2012061662A9 Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
12/06/2012WO2012012710A3 Radiation sensitization agents for prostate cancer
12/06/2012US20120309938 Hemiasterlin derivatives and uses thereof in the treatment of cancer
12/06/2012US20120309847 Dosing regimens and methods for treating or preventing promyelocytic leukemia
12/06/2012US20120309845 Dosing regimens and methods for treating or preventing acute myeloid leukemia
12/06/2012US20120309839 Dosing regimes for trans-clomiphene
12/06/2012US20120309836 Methods and compositions for administration of trpv1 agonists
1 ... 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 ... 2211